Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Editas Medicine (NQ: EDIT )

11.68 +0.82 (+7.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 27, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,574,516
Open 11.01
Bid (Size) 11.65 (3)
Ask (Size) 11.75 (1)
Prev. Close 10.86
Today's Range 10.70 - 11.75
52wk Range 9.710 - 73.03
Shares Outstanding 68,641,116
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Editas Medicine's Return On Capital Employed Insights
Benzinga Pro data, Editas Medicine (NASDAQ:EDIT) reported Q1 sales of $6.77 million. Earnings fell to a loss of $50.52 million, resulting in a 21.91% decrease from last quarter. 
Via Benzinga
The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga

Performance

YTD
-57.73%
-57.73%
1 Month
-16.15%
-16.15%
3 Month
-31.78%
-31.78%
6 Month
-62.64%
-62.64%
1 Year
-65.60%
-65.60%

More News

Read More
Expert Ratings for Editas Medicine
Via Benzinga
Editas Medicine: Q1 Earnings Insights
Via Benzinga
Editas Medicine Earnings Conference Call Is Coming Up, Here's What You Need To Know
Via Benzinga
Editas Medicine's EDIT-301 receives FDA Rare Pediatric Disease designation for Beta Thalassemia
Via Benzinga
Editas Medicine Stock Jumps As Patent Office Rules In Favor Of Broad's CRISPR Patents
Via Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
Via Benzinga
27 Stocks Moving in Monday's Pre-Market Session
Via Benzinga
Intellia Therapeutics Crashes As Patent Decision Clouds CRISPR Gene-Editing Test
Via Investor's Business Daily
Expert Ratings For Editas Medicine
Via Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Via Benzinga
Editas Suddenly Terminates Chief Medical Officer Without An Explanation
Via Benzinga
51 Biggest Movers From Yesterday
Via Benzinga
35 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
21 Stocks Moving in Tuesday's Pre-Market Session
Via Benzinga
Stock Market Rebound Fizzles Amid Hawkish Fed; Taiwan Semiconductor Breaks Out, JPMorgan Tumbles: Weekly Review
Via Investor's Business Daily
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks
Via Investor's Business Daily
Pfizer Makes Foray Into CRISPR, Inking $1.35 Billion Deal With Beam Therapeutics
Via Investor's Business Daily
Stocks Hitting New 52-Week Lows Today
Via Benzinga
Top 5 Moonshots for 2022 Countdown: My No. 5 Pick
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.